Pacjenci
Czym jest alergia?
Alergia na roztocza kurzu domowego
Alergia na pyłki
Życie z alergią
Skutki społeczno-ekonomiczne
Czym jest astma alergiczna?
Jak diagnozuje się alergię?
Leczenie alergii
Pracownicy ochrony zdrowia
Leczenie alergii i astmy
Produkty
Reakcje niepożądane
Rozpoczęcie leczenia
Program badań klinicznych
Prace badawczo-rozwojowe
Zrozumieć immunoterapię
Plan prac badawczo-rozwojowych
Badania naukowe
Kariera
Praca w firmie ALK
Wolne stanowiska
O firmie ALK
ALK w skrócie
Produkcja
Obecność na całym świecie
Organizacja
Historia
Wartości
Właściciele
Media
ALK GBSC
About Us
News
Careers
Contact
Zgłaszanie działań niepożądanych
Fulltext search
Search
Three-month interim report (Q1) 2025 (unaudited)
Read more
about Three-month interim report (Q1) 2025 (unaudited)
Link
https://www.globenewswire.com/news-release/2025/05/06/3074684/0/en/Three-month-…
Created date
Tue, 05/06/2025 - 12:00
Nasdaq ID
3074684
Last updated:
2025.05.09
ITULATEK® approved for treatment of children and adolescents in Canada
Read more
about ITULATEK® approved for treatment of children and adolescents in Canada
Link
https://www.globenewswire.com/news-release/2025/05/08/3077431/0/en/ITULATEK-app…
Created date
Thu, 05/08/2025 - 12:00
Nasdaq ID
3077431
Last updated:
2025.05.08
ALK enters into neffy® co-promotion agreement in the USA
Read more
about ALK enters into neffy® co-promotion agreement in the USA
Link
https://www.globenewswire.com/news-release/2025/05/02/3073224/0/en/ALK-enters-i…
Created date
Fri, 05/02/2025 - 12:00
Nasdaq ID
3073224
Last updated:
2025.05.02
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
Read more
about Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
Link
https://www.globenewswire.com/news-release/2025/04/29/3070453/0/en/Invitation-t…
Created date
Tue, 04/29/2025 - 12:00
Nasdaq ID
3070453
Last updated:
2025.04.29
ITULAZAX® tree pollen tablet approved for treatment of children in Europe
Read more
about ITULAZAX® tree pollen tablet approved for treatment of children in Europe
Link
https://www.globenewswire.com/news-release/2025/04/23/3066532/0/en/ITULAZAX-tre…
Created date
Wed, 04/23/2025 - 12:00
Nasdaq ID
3066532
Last updated:
2025.04.23
Market Access Manager
Read more
about Market Access Manager
EasyCruit ID
3477339
Department ID
189887
Location
England (North)
Vacancy URL
https://alkabello.easycruit.com/vacancy/3477339/189887
Expire Date
Thu, 09/11/2025 - 12:00
Last updated:
2025.04.25
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
Read more
about Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
Link
https://www.globenewswire.com/news-release/2025/04/03/3055331/0/en/Grant-of-sha…
Created date
Thu, 04/03/2025 - 12:00
Nasdaq ID
3055331
Last updated:
2025.04.03
Annual report 2024: ALK delivers 15% sales growth with profits up 65%
Read more
about Annual report 2024: ALK delivers 15% sales growth with profits up 65%
Link
https://www.globenewswire.com/news-release/2025/02/19/3028468/0/en/Annual-repor…
Created date
Wed, 02/19/2025 - 12:00
Nasdaq ID
3028468
Last updated:
2025.03.24
Annual General Meeting in ALK-Abelló A/S on 13 March 2025
Read more
about Annual General Meeting in ALK-Abelló A/S on 13 March 2025
Link
https://www.globenewswire.com/news-release/2025/02/19/3028793/0/en/Annual-Gener…
Created date
Wed, 02/19/2025 - 12:00
Nasdaq ID
3028793
Last updated:
2025.03.24
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Read more
about Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Link
https://www.globenewswire.com/news-release/2025/02/21/3030519/0/en/Report-on-tr…
Created date
Fri, 02/21/2025 - 12:00
Nasdaq ID
3030519
Last updated:
2025.03.24
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Page
3
Page
4
Current page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
Next ›
Last page
Last »
Subscribe to